GV

Activity from announced rounds

All recorded activity

GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.

Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.

GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.

Sources
Rounds participated in
49
Confirmed lead rounds
7
32 roles undisclosed
New companies
44
First participation on record · 5 follow-on
Funding in participating rounds
$30.3B
49 disclosed · full round size, not this investor’s share

By stage

Series C+15
Series A12
Series B12
Undisclosed5
Seed4
1 more
Growth1

By primary sector

AI11
Biotech10
Healthtech7
Cybersecurity6
Developer tools3
7 more
Enterprise software3
Defense tech2
Fintech2
Space tech2
Climate tech1
Foodtech1
Mobility1

By country

United States37
United Kingdom10
Bulgaria1
France1

Rounds

49 in all activity
Isomorphic Labs

Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas

$5BSeries C
Participant
Blacksmith

Cloud infrastructure for building and testing software through continuous integration workflows.

$66MSeries C
Participant
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A
Participant
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Participant
Allara

Virtual care for women with hormonal, metabolic and reproductive health needs.

$30MFunding
Participant
Armadin

Armadin develops AI agents that test attack paths across enterprise systems and show defenders how connected weaknesses could be exploited.

$255.5MSeries B
Participant
Metaview

Metaview provides AI agents and software for recruiters and hiring teams, from candidate sourcing and screening to interview notes and reporting.

$60MSeries C
Participant
Snorkel AI

Snorkel AI helps enterprises build expert-curated training data and benchmarks for advanced AI models and agents.

$350MSeries E
Participant
EnduroSat

EnduroSat designs and manufactures modular, software-defined satellites and components, and provides mission services for commercial and institutional operators.

$205MFunding round
Participant
Encoded Therapeutics Inc.

Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.

$275MSeries F
Lead
Blacksmith

Cloud infrastructure for building and testing software through continuous integration workflows.

$45MSeries B
Role not disclosed
LifeMine Therapeutics

Develops fungal genome-derived therapeutics for organ transplant rejection

$263MSeries D+Series E
Role not disclosed
Obsidian Security

Secures non-human identities and AI agents operating in third-party applications

$85MSeries D
Role not disclosed
Wonder

A leading food technology platform built to make great food more accessible

$650MSeries D
Role not disclosed
Nebex

Builds market infrastructure connecting space companies with sovereign buyers and capital

$30MSeed
Role not disclosed
Odyssey

Builds general-purpose world models that simulate physical reality for robotics, gaming, and autonomous systems

$310MSeries B
Role not disclosed
Contraline

Develops hormonal and non-hormonal male contraceptives for men and couples globally

$92.5MSeries B
Role not disclosed
MokN

Protects organisations from credential theft and identity-based attacks through active identity recovery technology

$15MSeries A
Role not disclosed
Signos, Inc.

Offers an FDA-cleared AI-powered glucose monitoring system for weight management and metabolic health

$20MGrowth
Role not disclosed
Flick

AI-native filmmaking platform giving creators cinematic control to direct AI-generated films

$6MSeed
Role not disclosed
Nectar Social

Provides AI infrastructure for modern marketing

$30MSeries A
Role not disclosed
Recursive Superintelligence

Develops self-improving AI systems that autonomously enhance their own architecture and training algorithms

$650MSeries A
Role not disclosed
Isomorphic Labs

Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas

$2.1BSeries B
Role not disclosed
Iterative Health

Develops technology and services for clinical research.

$77MSeries C
Role not disclosed
Wealth.com

Provides AI-powered estate and tax planning platform for wealth management firms

$65MSeries B
Role not disclosed
Censys

Provides Internet intelligence and insights for security operations and exposure management

$70MSeries D
Role not disclosed
Sift

Delivers AI data infrastructure for mission-critical machines across space, defense, and autonomy

$42MSeries B
Role not disclosed
Translucent

Provides AI platform for healthcare finance

$27MSeries A
Role not disclosed
Armadin

Armadin develops AI agents that test attack paths across enterprise systems and show defenders how connected weaknesses could be exploited.

$189.9MSeed+Series A
Role not disclosed
SambaNova

Provides next-generation AI infrastructure for enterprises, neo-clouds, and sovereign AI initiatives

$350MSeries E
Role not disclosed